Resveratrol shows efficacy against a wide range of cancers and neurodegeneration by targeting specific molecular pathways involved in cancer progression. It exhibits neuroprotective properties, which are crucial for reducing neurodegenerative diseases like Alzheimer's disease (AD). It works by reducing neuroinflammation, protecting neurons from oxidative damage, and controlling important signaling pathways that are essential for synaptic plasticity and neuronal survival. One of the main targets in cancer and neurodegenerative diseases, the kinase MARK4 is linked to the formation of tauopathies like AD. Resveratrol is an excellent antioxidant, anti-cancer and a neuroprotectant used as an inhibitor against the kinase MARK4. To comprehend the binding and structural changes in the protein's structure upon ligand binding, in silico investigations were conducted. After the in silico experiments, the pure protein was studied in vitro. With an IC50 value of 7 μ M, the natural substance resveratrol effectively inhibited the protein. Additionally, a significant binding affinity for MARK4 was demonstrated by the fluorescence binding experiment (K = 104 M−1). The findings demonstrated that the ligand attaches to the protein's binding pocket and blocks MARK4's enzymatic activity, indicating that the substance is a strong binding agent against MARK4.